ZIMLABZim Laboratories Ltd.

₹71.11-0.14%

Market Cap

₹348.80 Cr

Stock P/E

37.14

ROCE

10.11%

ROE

7.86%

Book Value

₹51.10

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

POSITIVES

•
FY25 has been a pivotal year for ZIM, a year marked by focused strategic execution, disciplined innovation and resilient business expansion amidst a challenging external environment.
•
The New Innovative Products and Oral Thin Film's sales together accounted for INR 624 million or 16.5% of total revenue.

NEGATIVES

•
Maharashtra government order delay due to election year; one order of INR 20 crores not received in FY25.
•
Regulatory risk and dependence on marketing partners to launch products create execution risk.

Peers Summary

Sector Leader

In the competitive landscape of pharmaceuticals, while Zim Laboratories Ltd. has shown some growth potential, it lags behind its peers in profitability and efficiency metrics. Companies like Mankind Pharma and Cipla Ltd. exhibit strong revenue growth and profitability, making them the leaders in this sector, whereas Zim Laboratories appears to be undervalued but struggles with declining revenue growth and lower margins.

Key Points

• Mankind Pharma and Cipla are standout performers in terms of profitability and growth.
• Zim Laboratories shows potential for value investment but has underperforming growth metrics.
• Divi's Laboratories and Sun Pharma are rated high on valuation but show weaker growth trajectories.

Top Performers

Mankind Pharma Ltd.

Strong revenue growth (YoY 18.12%) and high profitability metrics (ROE 23.15%).

Cipla Ltd.

Robust revenue growth (YoY 13.28%) and attractive valuation with a low PE ratio (23.73).

Dr. Reddy's Laboratories Ltd.

High profitability (ROE 21.76%) and strong growth trajectory (EPS growth 68.07%).

Explore

Watchlists

Command Palette